Page 301«..1020..300301302303..310320..»

Announcing New Professors in the Department of Internal Medicine – Yale School of Medicine

Posted: Published on November 5th, 2021

The Department of Internal Medicine is pleased to announce the following appointments and promotions to professor of medicine: Benjamin Doolittle, MD, M Div; Steven Pfau, MD; and Lisa Gale Suter, MD. Benjamin Doolittle, MD, M Div (General Internal Medicine) Director, Internal Medicine-Pediatrics Residency Program Professor, Religion and Health, Yale Divinity School Resident, Yale-New Haven Hospital (2002) MD, Yale School of Medicine (1997) MA Div, Yale Divinity School (1994) BS, Yale University (1991) Benjamin Doolittle, MD, M Div, is the program director of the Combined Internal Medicine-Pediatrics Residency Program, and the medical director of the Faculty-Resident Continuity Clinic Continue reading →

Posted in Clinical Cardiology | Comments Off on Announcing New Professors in the Department of Internal Medicine – Yale School of Medicine

Cardiovascular Systems, Inc. Announces First In-Human Experience With Coronary Everolimus Drug Coated Balloon – Business Wire

Posted: Published on November 5th, 2021

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the start of enrollment in a first in-human trial of the coronary everolimus drug-coated balloon (DCB) being developed by Chansu Vascular Technologies, LLC (CVT). Continue reading →

Posted in Clinical Cardiology | Comments Off on Cardiovascular Systems, Inc. Announces First In-Human Experience With Coronary Everolimus Drug Coated Balloon – Business Wire

Clare Oliver-Williams, Ph.D., to be recognized with the inaugural Dr. Nanette K. Wenger Research Goes Red Award for Best Scientific Publication on…

Posted: Published on November 5th, 2021

Embargoed until 7 a.m. CT / 8 a.m. ET Wednesday, Nov Continue reading →

Posted in Clinical Cardiology | Comments Off on Clare Oliver-Williams, Ph.D., to be recognized with the inaugural Dr. Nanette K. Wenger Research Goes Red Award for Best Scientific Publication on…

InspireMD Announces Publication of 12-Month Results of CGuard EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular…

Posted: Published on November 5th, 2021

InspireMD Announces Publication of 12-Month Results of CGuard EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions Tel Aviv, Israel- November 3, 2021 - InspireMD, Inc. Continue reading →

Posted in Clinical Cardiology | Comments Off on InspireMD Announces Publication of 12-Month Results of CGuard EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular…

Leslie A. Leinwand, Ph.D., of the University of Colorado, to receive the American Heart Association’s 2021 Eugene Braunwald Academic Mentorship Award…

Posted: Published on November 5th, 2021

Embargoed until 7 a.m. CT / 8 a.m Continue reading →

Posted in Clinical Cardiology | Comments Off on Leslie A. Leinwand, Ph.D., of the University of Colorado, to receive the American Heart Association’s 2021 Eugene Braunwald Academic Mentorship Award…

The American Heart Association’s 2021 Clinical Research Prize to be awarded to Joseph Woo, MD, of Stanford University – EurekAlert

Posted: Published on November 5th, 2021

Embargoed until 7 a.m. CT / 8 a.m. ET Wednesday, Nov. Continue reading →

Posted in Clinical Cardiology | Comments Off on The American Heart Association’s 2021 Clinical Research Prize to be awarded to Joseph Woo, MD, of Stanford University – EurekAlert

Vasan S. Ramachandran, MD, named the American Heart Association’s 2021 Distinguished Scientist in General Preventive Medicine – EurekAlert

Posted: Published on November 5th, 2021

Embargoed until 7 a.m. Continue reading →

Posted in Clinical Cardiology | Comments Off on Vasan S. Ramachandran, MD, named the American Heart Association’s 2021 Distinguished Scientist in General Preventive Medicine – EurekAlert

Kathryn J. Moore, Ph.D., FAHA, named the American Heart Association’s 2021 Distinguished Scientist in Arteriosclerosis, Thrombosis and Vascular…

Posted: Published on November 5th, 2021

Embargoed until 7 a.m. CT / 8 a.m. ET Wednesday, Nov. Continue reading →

Posted in Clinical Cardiology | Comments Off on Kathryn J. Moore, Ph.D., FAHA, named the American Heart Association’s 2021 Distinguished Scientist in Arteriosclerosis, Thrombosis and Vascular…

Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR – TCTMD

Posted: Published on November 5th, 2021

Among patients with severe mitral regurgitation (MR) who are poor candidates for surgery but survive a complex percutaneous procedure and its aftermath, mitral valve replacement (TMVR) with the Tendyne (Abbott) transcatheter device may reduce the severity of disease, improve symptoms, and lower the rate of hospitalization for heart failure over 2 years, according to new data. Yet two in five people treated died during follow-up, most within the first 3 months, leading some to insist that patient selection needs to be further refined before this procedure can be used more routinely. Continue reading →

Posted in Clinical Cardiology | Comments Off on Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR – TCTMD

Helixmith Announces Phase 3 Study Results of Novel Gene Therapy Treatment for Diabetic Foot Ulcers at 2021 Annual Meeting of Diabetic Foot Ulcer…

Posted: Published on October 24th, 2021

Data indicate that gene therapy appears to be effective, particularly in neuroischemic ulcers SAN DIEGO, Oct. 22, 2021 /PRNewswire/ -- Helixmith, a gene therapy company based in Seoul, Korea and San Diego, CA, announced today the results of a Phase 3 study for the treatment of diabetic foot ulcers with their novel gene therapy VM202 (Engensis) at the 2021 annual meeting of the Diabetic Foot Conference (DFCon) held in San Francisco and virtually. The study, "Gene Therapy for Diabetic Foot Ulcers: Analysis of a Randomized, Placebo-Controlled Phase 3 Study of Engensis (VM202), a Plasmid DNA Expressing Two Isoforms of Human Hepatocyte Growth Factor (HGF)," demonstrated a positive trend toward wound closure, potential healing effects and an acceptable safety profile Continue reading →

Posted in Hyperbaric Medicine | Comments Off on Helixmith Announces Phase 3 Study Results of Novel Gene Therapy Treatment for Diabetic Foot Ulcers at 2021 Annual Meeting of Diabetic Foot Ulcer…

Page 301«..1020..300301302303..310320..»